{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:22:50Z","timestamp":1762953770434,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1245\/s10434-020-09384-8","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T18:09:38Z","timestamp":1606154978000},"page":"3512-3521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era"],"prefix":"10.1245","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2263-3576","authenticated-orcid":false,"suffix":"III","given":"Richard J.","family":"Straker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne B.","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah S.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elnara","family":"Muradova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala","family":"Daou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Krause","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennie T.","family":"Frederick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen E.","family":"Rhodin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Brizel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevieve M.","family":"Boland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia M.","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan J.","family":"Wuthrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vernon K.","family":"Sondak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John N.","family":"Lukens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgos C.","family":"Karakousis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"9384_CR1","doi-asserted-by":"publisher","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472\u201392. https:\/\/doi.org\/10.3322\/caac.21409","DOI":"10.3322\/caac.21409"},{"issue":"14","key":"9384_CR2","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1200\/JCO.2009.27.1627","volume":"28","author":"CM Balch","year":"2010","unstructured":"Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28(14):2452\u20139. https:\/\/doi.org\/10.1200\/jco.2009.27.1627","journal-title":"J Clin Oncol."},{"issue":"2","key":"9384_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/s0360-3016(99)00431-9","volume":"46","author":"RJ Lee","year":"2000","unstructured":"Lee RJ, Gibbs JF, Proulx GM, Kollmorgen DR, Jia C, Kraybill WG. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. Jan 2000;46(2):467\u201374. https:\/\/doi.org\/10.1016\/s0360-3016(99)00431-9","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"9384_CR4","doi-asserted-by":"publisher","unstructured":"Strom T, Torres-Roca JF, Parekh A, et al. Regional radiation therapy impacts outcome for node-positive cutaneous melanoma. J Natl Compr Canc Netw. 2017;15(4):473\u201382. https:\/\/doi.org\/10.6004\/jnccn.2017.0047","DOI":"10.6004\/jnccn.2017.0047"},{"issue":"4","key":"9384_CR5","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/s0360-3016(01)02742-0","volume":"52","author":"MT Ballo","year":"2002","unstructured":"Ballo MT, Strom EA, Zagars GK, et al. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. 2002;52(4):964\u201372. https:\/\/doi.org\/10.1016\/s0360-3016(01)02742-0","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"7","key":"9384_CR6","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/cncr.11243","volume":"97","author":"MT Ballo","year":"2003","unstructured":"Ballo MT, Bonnen MD, Garden AS, et al. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer. 2003;97(7):1789\u201396. https:\/\/doi.org\/10.1002\/cncr.11243","journal-title":"Cancer."},{"issue":"12","key":"9384_CR7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1245\/ASO.2004.12.039","volume":"11","author":"MT Ballo","year":"2004","unstructured":"Ballo MT, Zagars GK, Gershenwald JE, et al. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol. 2004;11(12):1079\u201384. https:\/\/doi.org\/10.1245\/aso.2004.12.039","journal-title":"Ann Surg Oncol."},{"issue":"24","key":"9384_CR8","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.1002\/cncr.24627","volume":"115","author":"S Agrawal","year":"2009","unstructured":"Agrawal S, Kane JM, Guadagnolo BA, Kraybill WG, Ballo MT. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer. 2009;115(24):5836\u201344. https:\/\/doi.org\/10.1002\/cncr.24627","journal-title":"Cancer."},{"issue":"6","key":"9384_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1470-2045(12)70138-9","volume":"13","author":"BH Burmeister","year":"2012","unstructured":"Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012;13(6):589\u201397. https:\/\/doi.org\/10.1016\/s1470-2045(12)70138-9","journal-title":"Lancet Oncol."},{"key":"9384_CR10","doi-asserted-by":"publisher","unstructured":"Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16(9):1049\u201360. https:\/\/doi.org\/10.1016\/s1470-2045(15)00187-4","DOI":"10.1016\/s1470-2045(15)00187-4"},{"key":"9384_CR11","doi-asserted-by":"publisher","unstructured":"Wuthrick EJ, Chablani P. Do not forget about the importance of loco-regional therapy in melanoma management. Semin Radiat Oncol. 2019;29(2):166\u201370. https:\/\/doi.org\/10.1016\/j.semradonc.2018.11.006","DOI":"10.1016\/j.semradonc.2018.11.006"},{"key":"9384_CR12","unstructured":"Network NCC. Cutaneous Melanoma, Version 3.2020,\u00a0NCCN\u00a0Clinical Practice Guidelines in Oncology. Accessed September 6, 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf"},{"key":"9384_CR13","doi-asserted-by":"publisher","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845\u201355. https:\/\/doi.org\/10.1056\/nejmoa1611299","DOI":"10.1056\/nejmoa1611299"},{"key":"9384_CR14","doi-asserted-by":"publisher","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335. https:\/\/doi.org\/10.1056\/nejmoa1709030","DOI":"10.1056\/nejmoa1709030"},{"key":"9384_CR15","doi-asserted-by":"publisher","unstructured":"Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813\u201323. https:\/\/doi.org\/10.1056\/nejmoa1708539","DOI":"10.1056\/nejmoa1708539"},{"key":"9384_CR16","doi-asserted-by":"publisher","unstructured":"Maio M, Lewis K, Demidov L, et al. Adjuvant vemurafenib in resected, BRAF. Lancet Oncol. 2018;19(4):510\u201320. https:\/\/doi.org\/10.1016\/s1470-2045(18)30106-2","DOI":"10.1016\/s1470-2045(18)30106-2"},{"issue":"19","key":"9384_CR17","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u20131801. https:\/\/doi.org\/10.1056\/nejmoa1802357","journal-title":"N Engl J Med."},{"issue":"13","key":"9384_CR18","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1245\/s10434-019-07599-y","volume":"26","author":"Y Song","year":"2019","unstructured":"Song Y, Tieniber AD, Gimotty PA, et al. Survival outcomes of patients with clinical stage III melanoma in the era of novel systemic therapies. Ann Surg Oncol. 2019;26(13):4621\u201330. https:\/\/doi.org\/10.1245\/s10434-019-07599-y","journal-title":"Ann Surg Oncol."},{"key":"9384_CR19","doi-asserted-by":"publisher","unstructured":"Tarhini A, Lin Y, Lin H, et al. Neoadjuvant ipilimumab (3\u00a0mg\/kg or 10\u00a0mg\/kg) and high dose IFN-\u03b12b in locally\/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer. 2018;6(1):112. https:\/\/doi.org\/10.1186\/s40425-018-0428-5","DOI":"10.1186\/s40425-018-0428-5"},{"key":"9384_CR20","doi-asserted-by":"publisher","unstructured":"Huang AC, Orlowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25(3):454\u201361. https:\/\/doi.org\/10.1038\/s41591-019-0357-y","DOI":"10.1038\/s41591-019-0357-y"},{"key":"9384_CR21","doi-asserted-by":"publisher","unstructured":"Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655\u201361. https:\/\/doi.org\/10.1038\/s41591-018-0198-0","DOI":"10.1038\/s41591-018-0198-0"},{"issue":"7","key":"9384_CR22","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"20","author":"EA Rozeman","year":"2019","unstructured":"Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948\u201360. https:\/\/doi.org\/10.1016\/s1470-2045(19)30151-2","journal-title":"Lancet Oncol."},{"key":"9384_CR23","doi-asserted-by":"publisher","unstructured":"Amaria RN, Prieto PA, Tetzlaff MT, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018;19(2):181\u201393. https:\/\/doi.org\/10.1016\/s1470-2045(18)30015-9","DOI":"10.1016\/s1470-2045(18)30015-9"},{"key":"9384_CR24","doi-asserted-by":"publisher","unstructured":"Long GV, Saw RPM, Lo S, et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF. Lancet Oncol. 2019;20(7):961\u201371. https:\/\/doi.org\/10.1016\/s1470-2045(19)30331-6","DOI":"10.1016\/s1470-2045(19)30331-6"},{"key":"9384_CR25","doi-asserted-by":"publisher","unstructured":"Amaria RN, Reddy SM, Tawbi HA, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(11):1649\u201354. https:\/\/doi.org\/10.1038\/s41591-018-0197-1","DOI":"10.1038\/s41591-018-0197-1"},{"issue":"1","key":"9384_CR26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijrobp.2020.06.006","volume":"108","author":"D Mitra","year":"2020","unstructured":"Mitra D, Bishop A, Guadagnolo BA. Adjuvant nodal radiation therapy for melanoma in the era of immunotherapy. Int J Radiat Oncol Biol Phys. 2020;108(1):164\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.06.006","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"5","key":"9384_CR27","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341\u20136. https:\/\/doi.org\/10.1016\/0360-3016(95)00060-c","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"8","key":"9384_CR28","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-11-2097","volume":"18","author":"JJ Dignam","year":"2012","unstructured":"Dignam JJ, Zhang Q, Kocherginsky M. The use and interpretation of competing risks regression models. Clin Cancer Res. 2012;18(8):2301\u20138. https:\/\/doi.org\/10.1158\/1078-0432.ccr-11-2097","journal-title":"Clin Cancer Res."},{"issue":"4","key":"9384_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-x","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343\u20136. https:\/\/doi.org\/10.1016\/0197-2456(96)00075-x","journal-title":"Control Clin Trials."},{"key":"9384_CR30","unstructured":"StataCorp. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC; 2019."},{"key":"9384_CR31","doi-asserted-by":"publisher","unstructured":"Barker CA. Adjuvant pembrolizumab in resected stage III melanoma. N Engl J Med. 2018;379(6):593. https:\/\/doi.org\/10.1056\/nejmc1807505","DOI":"10.1056\/nejmc1807505"},{"key":"9384_CR32","doi-asserted-by":"publisher","unstructured":"Hauschild A, Dummer R, Schadendorf D, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected. J Clin Oncol. 2018;36(35):3441\u20139. https:\/\/doi.org\/10.1200\/jco.18.01219","DOI":"10.1200\/jco.18.01219"},{"issue":"1","key":"9384_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2217\/mmt.15.41","volume":"3","author":"CE Kan","year":"2016","unstructured":"Kan CE, Mansur DB. The role of radiation therapy in the management of cutaneous melanoma. Melanoma Manag. 2016;3(1):61\u201372. https:\/\/doi.org\/10.2217\/mmt.15.41","journal-title":"Melanoma Manag."},{"key":"9384_CR34","doi-asserted-by":"publisher","unstructured":"Burmeister BH, Mark Smithers B, Burmeister E, et al. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) Study 96.06. Radiother Oncol. 2006;81(2):136\u201342. https:\/\/doi.org\/10.1016\/j.radonc.2006.10.001","DOI":"10.1016\/j.radonc.2006.10.001"},{"issue":"7","key":"9384_CR35","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","volume":"15","author":"B Fisher","year":"1997","unstructured":"Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483\u201393. https:\/\/doi.org\/10.1200\/jco.1997.15.7.2483","journal-title":"J Clin Oncol."},{"key":"9384_CR36","doi-asserted-by":"publisher","unstructured":"Group MRCOCW. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359(9319):1727\u201333. https:\/\/doi.org\/10.1016\/s0140-6736(02)08651-8","DOI":"10.1016\/s0140-6736(02)08651-8"},{"issue":"9","key":"9384_CR37","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859\u201366. https:\/\/doi.org\/10.1056\/nejmoa022148","journal-title":"N Engl J Med."},{"key":"9384_CR38","doi-asserted-by":"publisher","unstructured":"Versluis JM, Long GV, Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med. 2020;26(4):475\u201384. https:\/\/doi.org\/10.1038\/s41591-020-0829-0","DOI":"10.1038\/s41591-020-0829-0"},{"issue":"2","key":"9384_CR39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11864-020-0700-z","volume":"21","author":"MS Pelster","year":"2020","unstructured":"Pelster MS, Amaria RN. Neoadjuvant immunotherapy for locally advanced melanoma. Curr Treat Options Oncol. 2020;21(2):10. https:\/\/doi.org\/10.1007\/s11864-020-0700-z","journal-title":"Curr Treat Options Oncol."},{"issue":"3","key":"9384_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4103\/0019-5154.131383","volume":"59","author":"V Deshmane","year":"2014","unstructured":"Deshmane V, Kalloli M, Chikaraddi S, Keerthi B, Krishnappa R. Predictive factors for loco regional recurrence and distant metastasis following primary surgical treatment of cutaneous melanoma. Indian J Dermatol. 2014;59(3):241\u20136. https:\/\/doi.org\/10.4103\/0019-5154.131383","journal-title":"Indian J Dermatol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09384-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-09384-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09384-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T13:21:38Z","timestamp":1623072098000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-09384-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["9384"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-09384-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"assertion":[{"value":"21 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Sondak reports personal fees from Array, Bristol Myers Squibb, Genentech, Merck, Novartis, Pfizer, Regeneron, and Replimune, outside the submitted work. Dr. Wuthrick reports personal fees from Varian and Sanofi, outside the submitted work. Dr. Zager reports advisory board participation with Merck, Amgen, and Sanofi Regeneron; speakers bureau participation with Array Biopharma and Sun Pharma; and research work with Amgen, Provectus, Castle Biosciences, and Delcath Systems, all outside the submitted work. Dr. Boland has sponsored research agreements with Palleon Pharmaceuticals and Olink Proteomics. She served on scientific advisory boards for Nektar Therapeutics and Novartis. She has received honoraria from Novartis and Takeda Pharmaceutics. She served as a consultant to Northwest Biotherapeutics. Dr. Georgia Beasley reports relevant financial activities outside the submitted work as a member of the 2020 Regeneron Sanofi advisory board. Other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"All authors have reviewed and approved the submitted manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}